Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 36kWORD 17k
12 March 2020
Answer given by Ms Kyriakides
on behalf of the European Commission
Question reference: E-000480/2020

Measures regulating the prices and reimbursement of medicines within the EU are a national competence(1). I n order to ensure the functioning of the internal market, Council Directive 89/105/EEC(2) lays down procedural rules (such as time limits, motivation and judicial appeal) applicable to such measures.

Moreover, t he Commission is committed to supporting Member States in constantly improving the quality and sustainability of their health systems(3) and addressing the challenges linked to affordable medicines.

The 2019 EU State of Health report(4) highlights ways that the EU can help decisions at national and local level, such as sharing experiences on pricing and payment methods at EU level.

As part of the preparatory work for the EU pharmaceutical strategy, due at the end of 2020, the Commission will consult stakeholders, including the Association of Mutual Benefit Societies on issues related to affordability. Options such as those mentioned by the Honourable Member will be considered, as far as they are relevant to EU level policies.

(1)Articles 34, 36 and 168(7) Treaty on the Functioning of the EU: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:12012E/TXT&from=EN
Last updated: 17 March 2020Legal notice - Privacy policy